Standard BioTools Inc. (NASDAQ:LAB) opened Monday’s trading higher.
The company driven announced the launch of the Hyperion+™ Imaging System, the new standard in high-plex spatial imaging, providing lower limits of detection as well as improved sample capacity and time to results.
The Hyperion™+ Imaging System provides researchers with a deep understanding of disease and response to treatment, with the ability to stratify subjects by linking high-plex data to outcomes in clinical studies.
The system can process 100-plus samples per week, performing at twice the speed of the current Hyperion Imaging System, with a 1.6x lower limit of detection. This enables detection of dim markers, an advantage that can be critical for lower-expressing markers often used in translational studies.
Results of a study using the Hyperion+ Imaging System to improve understanding of the biology and pathophysiology of the tumor microenvironment in pancreatic invasive ductal adenocarcinoma (PDAC) will be presented today in a poster session at the annual meeting of the American Association for Cancer Research (AACR) in New Orleans.
Key benefits of the Hyperion+ Imaging System include: Superior phenotyping based on quantitative, high-quality single-cell data from biomarkers using 25 to more than 100 slides per week, generated with no autofluorescence or multiple staining and imaging cycles that limit throughput. These high-quality data help customers make fast and confident translational research decisions.
Up to 10x cost savings compared with immunohistochemistry using an efficient, simple stain-image-analyze workflow in contrast to other complicated cyclic immunofluorescence or digital profiling approaches.
LAB shares advanced 15 cents, or 4% to $3.95.
